Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

What Was Tested

This randomized controlled trial paper looks at Retatrutide and Glucagon.

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

The researchers conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Retatrutide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Retatrutide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Retatrutide group a baseline to be compared against.

The primary end point was the percentage change in body weight from baseline to 24 weeks.

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Glucagon-Like Peptide 1, Obesity, Weight Loss, Gastric Inhibitory Polypeptide, Receptors, Glucagon and Anti-Obesity Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide and Glucagon.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (The New England journal of medicine), a journal based in United States.

More context: the Retatrutide compound page and the Glucagon compound page, all human trials.